Trials / Terminated
TerminatedNCT01054443
A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of S-888711 Tablets Administered Once-daily for 42 Days to Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Shionogi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study was to assess the efficacy of 3 dose levels of lusutrombopag (0.5 mg, 0.75 mg, and 1.0 mg) and placebo on platelet count.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Tablet |
| DRUG | Lusutrombopag | Tablet |
Timeline
- Start date
- 2010-03-18
- Primary completion
- 2010-11-24
- Completion
- 2010-11-24
- First posted
- 2010-01-22
- Last updated
- 2021-03-18
- Results posted
- 2021-02-24
Locations
19 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01054443. Inclusion in this directory is not an endorsement.